{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106544","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.290029+00:00","generated_at":"2026-05-17T15:26:07.636835+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tempest Therapeutics reports Q2 2025 net loss $7.9M; cash $14.3M; pivotal HCC trial cleared in China","bullets":["Cash and equivalents at June 30, 2025: $14.3M, down from $30.3M at Dec 31, 2024.","Net loss Q2 2025: $7.9M ($2.07 per share) vs $9.6M ($5.52) in Q2 2024.","R&D expense Q2 2025: $3.9M, down from $5.8M due to re-prioritization toward strategic alternatives.","Received clearance to start pivotal trial of amezalpat combo for first-line HCC in China; EMA orphan drug designation granted.","Completed $4.6M registered direct offering in June 2025; net proceeds $4.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106544","json":"https://secwatch.observer/filing/0000950170-25-106544.json","markdown":"https://secwatch.observer/filing/0000950170-25-106544.md","text":"https://secwatch.observer/filing/0000950170-25-106544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017025106544/0000950170-25-106544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017025106544/tpst-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:26:07.636835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}